ArticleCancers2023
The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 79 citations in OpenAlex.
- Possible Applications of Cold Atmospheric Plasma in Otorhinolaryngology: A Narrative Review.Antioxidants (Basel, Switzerland) · 2026Review
- Redox-modulation of regulated cell death: implications for synergistic anticancer therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Synergistic Sensitization of Pancreatic Cancer Cells by Nanosecond Pulsed Electric Fields and Cold Atmospheric Plasma via Amplifying ROS and Apoptotic Signaling.International journal of molecular sciences · 2026Article
- Cold Atmospheric Plasma in Biomedicine and Pharmacology: Multidisciplinary Perspectives on Therapeutic Applications.ACS pharmacology & translational science · 2026Review
- Ventilator-integrated humidified cold atmospheric plasma enables safe eradication of lung cancer cells and supports respiratory therapeutic applications.Scientific reports · 2026Article
- Reactive oxygen species in health and disease.Molecular biomedicine · 2026Review
- Penetration depth of cold atmospheric plasma into biological tissue: a review.Frontiers in bioengineering and biotechnology · 2026Review
- Short cold atmospheric plasma treatment preserves vascular quiescence in 3D tumor-stroma-endothelial models of pancreatic cancer in vitro and in ovo.NPJ precision oncology · 2025Article
- Article
- Cold atmospheric plasma is a promising strategy for treating diabetic retinopathy.Journal of translational medicine · 2025Review
- Cold Atmospheric Plasma Selectively Disrupts Breast Cancer Growth in a Bioprinted 3D Tumor-Stroma Co-Culture Model.Advanced healthcare materials · 2025Article
- Advances in cold atmospheric plasma therapy for cancer.Bioactive materials · 2025Review
- The activity of cold atmospheric plasma against high-grade glioma: a review.Journal of neuro-oncology · 2025Review
- Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.Antioxidants (Basel, Switzerland) · 2025Review
- Article
- Cold atmospheric plasma effectively kills chordoma cells through induction of intracellular reactive oxygen species.Scientific reports · 2025Article
- Article
- Synergistic potential of CDH3 in targeting CRC metastasis and enhancing immunotherapy.BMC cancer · 2025Article
- Cold Atmospheric Plasma in Oncology: A Review and Perspectives on Its Application in Veterinary Oncology.Animals : an open access journal from MDPI · 2025Review
- Anti-Tumor Effect of Non-Thermal Atmospheric Pressure Plasma-Activated Medium on Synovial Sarcoma: An In Vitro and In Vivo Study.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Funding
Abstract
Local regional recurrence (LRR) remains the primary cause of treatment failure in solid tumors despite advancements in cancer therapies. Canady Helios Cold Plasma (CHCP) is a novel Cold Atmospheric Plasma device that generates an Electromagnetic Field and Reactive Oxygen and Nitrogen Species to induce cancer cell death. In the first FDA-approved Phase I trial (March 2020-April 2021), 20 patients with stage IV or recurrent solid tumors underwent surgical resection combined with intra-operative CHCP treatment. Safety was the primary endpoint; secondary endpoints were non-LRR, survival, cancer cell death, and the preservation of surrounding healthy tissue. CHCP did not impact intraoperative physiological data (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.